Unknown PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01443689

Allogenic Stem Cell Therapy in Patients With Acute Burn

A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Acute Burn

Sponsor: Shenzhen Beike Bio-Technology Co., Ltd.

Conditions Burns

Interventions Conventional therapy human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells human umbilical cord mesenchymal stem cells

Updated 5 times since 2017 Last updated: Nov 26, 2012 Started: Jul 31, 2011 Primary completion: Mar 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01443689, this PHASE1/PHASE2 trial focuses on Burns and remains ongoing. Sponsored by Shenzhen Beike Bio-Technology Co., Ltd., it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen Beike Bio-Technology Co., Ltd.
The Second Affiliated Hospital of Kunming Medical University

Data source: Shenzhen Beike Bio-Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kunming, China